AskBio’s gene therapy shows promising 12-month results for heart failure
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Subscribe To Our Newsletter & Stay Updated